IntelliPharmaCeutics Intl (IPCI) Upgraded at ValuEngine

ValuEngine upgraded shares of IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) from a hold rating to a buy rating in a report published on Friday.

Several other equities analysts have also recently commented on IPCI. HC Wainwright set a $30.00 price target on shares of IntelliPharmaCeutics Intl and gave the company a buy rating in a research report on Tuesday, May 29th. Zacks Investment Research cut shares of IntelliPharmaCeutics Intl from a hold rating to a sell rating in a research report on Saturday, June 2nd. Finally, Maxim Group reissued a hold rating and issued a $80.00 price target on shares of IntelliPharmaCeutics Intl in a research report on Friday, June 15th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. IntelliPharmaCeutics Intl has an average rating of Hold and an average price target of $36.50.

Shares of IPCI stock opened at $2.95 on Friday. IntelliPharmaCeutics Intl has a 52 week low of $2.30 and a 52 week high of $12.50.

IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last issued its quarterly earnings results on Monday, July 16th. The company reported ($0.70) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.70). The business had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $0.90 million. analysts forecast that IntelliPharmaCeutics Intl will post -0.2 EPS for the current fiscal year.

An institutional investor recently bought a new position in IntelliPharmaCeutics Intl stock. Anson Funds Management LP acquired a new position in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 2,128,720 shares of the company’s stock, valued at approximately $1,210,000. IntelliPharmaCeutics Intl comprises approximately 0.9% of Anson Funds Management LP’s investment portfolio, making the stock its 17th largest position. Anson Funds Management LP owned about 4.89% of IntelliPharmaCeutics Intl at the end of the most recent reporting period. Institutional investors and hedge funds own 20.52% of the company’s stock.

IntelliPharmaCeutics Intl Company Profile

IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.

Further Reading: Average Daily Trade Volume – ADTV

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply